BeiGene

Cancer has no borders. Neither do we.

BeiGene is a global biotechnology company focused on discovering, developing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. **Founded in 2010** by Xiaodong Wang, Ph.D., and John V. Oyler, the company has colleagues on **five continents** and offices around the world including the United States, China, Australia, and Europe.

Today, BeiGene **markets 16** internally-developed and partnered medicines in China. The company's BTK inhibitor BRUKINSA® is approved in **47** markets around the world, including the United States, China, European Union, Great Britain, Canada, Australia and South Korea in selected indications. BRUKINSA has new indication applications under review by the U.S. FDA and European Medicines Authority for treatment of chronic lymphocytic leukemia, the most common form of leukemia in adults.

In the company's first 10 years, 11 internally-developed molecules were advanced into the clinic. Three medicines developed in BeiGene labs have been approved by regulatory authorities: **BTK inhibitor BRUKINSA**; **anti-PD-1 monoclonal antibody Tislelizumab**, and **PARP inhibitor Pamiparib**.

BeiGene has developed internal, **state-of-the-art manufacturing** capabilities that bring cost savings, agility, and flexibility. Currently, the company has existing facilities in **Guangzhou, China** focused on biologics, and a multi-functional manufacturing facility in **Suzhou, China**. In Q2 2022, BeiGene broke ground on a new U.S. R&D and manufacturing site at the Princeton West Innovation Center in **Hopewell, N.J**.

Our Collaborations

in 2019

Amgen Inc. acquired **20.5%** of BeiGene in a deal valued at **$2.7 billion**. In turn, BeiGene acquired the rights to commercialize three Amgen pharmaceuticals, XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab), in China as well as to jointly develop a number of investigational assets in Amgen's oncology pipeline.

in 2021

BeiGene partnered with Novartis to develop, manufacture, and commercialize tislelizumab in North America, Japan, and Europe. BeiGene received **$650 million** in upfront payments and is eligible to receive up to **$1.55 billion** in potential regulatory and sales milestone payments plus royalties on product sales. Later in the year, the collaboration expanded to include BeiGene's Phase 3 anti-TIGIT antibody ociperlimab under an exclusive option agreement with a **$300 million** upfront payment and additional **$600** or **$700** million upon exercise of the option.

BeiGene at a Glance

Year Founded: **2010**

Co-founder, Chairman and CEO: **John V. Oyler**

Corporate Offices: **Cambridge, Mass; Beijing, China and Basel, Switzerland**

Nasdaq Ticker: **BGNE**

HKEX Ticker: **06160**

SSE Ticker: **688235**

Number of Offices: **30**

Number of Industry Collaborations: **~20**

Number of Employees: **8,000+**

Global Clinical Development: **45 Countries**

World-Class R&D Engine

Molecules to the Clinic in First 10 Years: **11**

Internally-Discovered Approved Medicines: **3**

Late-Stage Programs: **4**

Early-Stage Programs: **8**

Preclinical Programs Ongoing: **50+**

Molecules at Commercial or Clinical Stage: **~50**

Phase 3 or Potentially Registration-Enabling Trials: **30+**

Oncology Research Team: **700+**

Our Marketed Internally-Developed Medicines



Tislelizumab

Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcR on macrophages. Tislelizumab is the first medicine from BeiGene's immuno-oncology biologics program and is being developed internationally as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. Tislelizumab has received market authorization from the China National Medical Products Administration (NMPA) in eight indications, and is under development for additional approvals globally. The global tislelizumab clinical development program includes more than 9,000 subjects enrolled to-date in more than 35 countries and regions.

BRUKINSA (zanubrutinib)

BRUKINSA is a small molecule inhibitor of Bruton's tyrosine kinase (BTK) discovered by BeiGene scientists that is currently being evaluated globally in a broad clinical program as a monotherapy and in combination with other therapies to treat various B-cell malignancies. Because new BTK is continuously synthesized, BRUKINSA was specifically designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. With differentiated pharmacokinetics compared to other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B-cells within a number of disease relevant tissues. To date, BRUKINSA is approved in 47 markets, including the United States, China, European Union, Great Britain, Canada, Australia and South Korea in selected indications and under development for additional approvals globally. The global BRUKINSA development program includes nearly 4,000 subjects enrolled to-date in more than 25 countries and regions.



Pamiparib

An inhibitor of PARP1 and PARP2 which has demonstrated pharmacological properties such as brain penetration and PARP-DNA complex trapping in preclinical models. Discovered by BeiGene scientists, pamiparib is currently in global clinical development as a monotherapy or in combination with other agents for a variety of solid tumor malignancies. Pamiparib is not approved for use outside China.

BNGE-22-026-US REV 5-22

Numbers as of May 2022